Navigation Links
Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
Date:4/15/2008

>

"MEK inhibitors may have broad utility in the treatment of human cancers and inflammatory diseases. We are pleased to have two compounds in this class, both with excellent preclinical profiles and promising human pharmacokinetics, moving forward in clinical development," said Barry D. Quart, PharmD, Ardea Biosciences' President and CEO. "We constantly strive to diminish the inherent risk of drug development by having multiple compounds, from structurally different chemical classes, moving through development and we are excited to complete Phase 1 testing of our lead MEK inhibitor, RDEA119, and progress RDEA436 into Phase 1 clinical testing, in the second half of 2008."

The posters are available on the Company website (http://www.ardeabio.com/) under the titles "RDEA119, a Potent and Highly Specific MEK Inhibitor is Efficacious in Mouse Tumor Xenograft Studies" and "RDEA436, a Novel MEK Inhibitor with Favorable Pharmacokinetic Properties."

About RDEA119 and RDEA436

RDEA119 and RDEA436, non-ATP competitive, highly-selective MEK inhibitors for the treatment of cancer and inflammatory diseases, are two of the compounds from Ardea's MEK inhibitor research and development program. RDEA119 has shown potential as a potent and selective inhibitor of MEK, which is believed to play an important role in cancer cell proliferation, apoptosis and metastasis. Preclinical and clinical results suggest that RDEA119 has favorable properties, including oral dosing, excellent selectivity and limited retention in the brain, which, in turn, may result in a reduced risk of central nervous system (CNS) side effects. Preclinical data shows that RDEA436 is a potent in vitro and in vivo inhibitor of MEK, has favorable pharmacokinetic properties with low CNS penetration and a long half-life in a human micro-dose study indicating the potential for once daily dosing in humans.

About Ardea Biosciences

Ardea
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
9. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
10. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
11. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014 According to a new ... (RFID) Market (Tags, Readers, Middleware, Printers and Cabinets) - ... 2014 - 2020" the global radiofrequency identification (RFID) market ... is expected to grow at a CAGR of 13.9% ... of USD 5.3 billion in 2020. Browse ...
(Date:8/28/2014)... PITTSBURGH , Aug. 28, 2014 /PRNewswire-iReach/ -- ... exhibiting at the 9 th Annual Global ... , September 8-9 th . The Global ... industry leaders in small molecule and biologic pharmaceutical ... address challenges that today,s manufacturers face, such as ...
(Date:8/28/2014)... , Aug. 28, 2014  Stryker Orthopaedics, the Official Joint ... bringing its message of joint health to golf fans at ... at the Deutsche Bank Championship. The company,s fan destination – ... Fan Zone on 9" at the TPC Boston in ... th .    At the Deutsche Bank Championship, ...
Breaking Medicine Technology:Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 2Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 3Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 4Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 5Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 2Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 3Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 2Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 3Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 4Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 5
... 11 CEL-SCI Corporation (NYSE CVM), a ... for the prevention and treatment of infectious diseases, announced today ... manufacturing equipment at its GMP manufacturing facility in Maryland. Completion ... it allows CEL-SCI to move forward with its drug manufacturing ...
... ... , , , , BOTHELL, Wash., Jan. 11 ... in automated external defibrillator ( AED ) and diagnostic cardiac monitoring devices, has ... development and commercialization of simple, cost-effective medical products and services that positively impact ...
Cached Medicine Technology:CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine 2CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine 3CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine 4Cardiac Science and Gust Bardy, MD Create Innovation Center for Primary Care Medicine 2Cardiac Science and Gust Bardy, MD Create Innovation Center for Primary Care Medicine 3Cardiac Science and Gust Bardy, MD Create Innovation Center for Primary Care Medicine 4Cardiac Science and Gust Bardy, MD Create Innovation Center for Primary Care Medicine 5Cardiac Science and Gust Bardy, MD Create Innovation Center for Primary Care Medicine 6Cardiac Science and Gust Bardy, MD Create Innovation Center for Primary Care Medicine 7
(Date:8/28/2014)... A fortuitous collaboration at Rice University has led ... natural antibiotic. , The laboratory recreation of a ... the fight against bacteria that evolve resistance to ... , As part of the process, Rice ... Shamoo and their colleagues created and tested a ...
(Date:8/28/2014)... nerves with adhesives, most researchers place glue directly on ... the nerve ends well and allows glue to easily ... However, it is difficult to insert the nerve ends ... there is frictional resistance. Xiangdang Liang and co-workers from ... conduit for the adhesive technique and defined the best ...
(Date:8/28/2014)... can be treated with nasal septum cells. Researchers at ... that cells taken from the nasal septum are able ... and can thus repair articular cartilage defects. The nasal ... joint environment is associated with the expression of so-called ... has published the research results together with the ...
(Date:8/28/2014)... every 200 Ontarians has been diagnosed with inflammatory bowel ... the disease increasing by 64 per cent between 1999 ... the Institute for Clinical Evaluative Sciences (ICES), the Children,s ... Research Institute. That puts Ontario in the 90th percentile ... published this week in Inflammatory Bowel Diseases , ...
(Date:8/28/2014)... seven per cent of rheumatoid arthritis patients in the ... as anti-TNF therapies did not take them as prescribed ... Infirmary were among those from 60 hospitals around the ... Arthritis Research UK Centre for Genetics and Genomics at ... that failure to take the drugs correctly, known as ...
Breaking Medicine News(10 mins):Health News:Synthesis produces new antibiotic 2Health News:Synthesis produces new antibiotic 3Health News:Synthesis produces new antibiotic 4Health News:From nose to knee: Engineered cartilage regenerates joints 2Health News:Ontario has one of the highest rates of IBD in the world 2Health News:Arthritis patients failing to take expensive medication, according to new research 2
... the malaria parasites to attack the red blood cells. ... Cell, will help the scientists in designing vaccines against ... through which malaria parasites invade red blood cells is ... merozoites called EBA-175 to a receptor protein on the ...
... a smart bomb for cancer treatment is to be reported ... into the tumor, seal the opening and then deliver ... This will leave the healthy cells unharmed. ,The ... cancer have the potential of being a revolutionary form of ...
... those people suffering from tension-headaches, acupuncture may be the ... journal BMJ said that acupuncture can reduce the incidence ... - the gold standard of clinical trials - researchers ... of tension headache into three groups. ,Over ...
... delays healing of physical wounds, a new study says//. ... of Illinois at Chicago in a study of laboratory ... delayed the closing of wounds by more than 45 ... of cell and genetic changes accounted for the slow ...
... and happen even when people are not aware of their ... 2005 issue of Nature. ,Researchers from University of California, ... Affairs Health System had undertaken the study to find out ... when they are actually not aware of doing so. ...
... A new study by scientists in Japan may help ... UPI. ,Richard Smith, a research professor in otolaryngology ... University gave a genetically deafened mouse interfering RNA (Ribonucleic ... that would otherwise cause deafness. ,"By preventing its ...
Cached Medicine News:Health News:Researchers Discover Protein That Causes Malaria 2Health News:An Anti-cancer Smart Bomb delivered using a Nanocell 2Health News:An Anti-cancer Smart Bomb delivered using a Nanocell 3Health News:Acupuncture May Be An Effective Treatment Against Tension-Headaches 2Health News:Habit Memory May Enhance Learning In People 2
... products for autoimmune testing feature single-well ANA ... as specific reflex tests including dsDNA, and ... (Ro), SS-B (La), Scl-70 and Jo-1. In ... full line of products for Cardiolipins (IgA, ...
... Our ELISA products for autoimmune testing feature ... as well as specific reflex tests including ... Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 and ... includes a full line of products for ...
... products for autoimmune testing feature single-well ANA ... as specific reflex tests including dsDNA, and ... (Ro), SS-B (La), Scl-70 and Jo-1. In ... full line of products for Cardiolipins (IgA, ...
... is a leading provider of immunofluorescence assays, ... menu that includes kits for autoimmune diseases, ... miscellaneous conjugates and components. Our Impact IFA ... of substrates and kit sizes to choose ...
Medicine Products: